It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM Quick QuoteMIRM - Free Report) . Shares have added about 1.3% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.

Mirum Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

Mirum reported earnings of 5 cents per share for the third quarter of 2025 against the Zacks Consensus Estimate of a loss of 10 cents. The company had incurred a loss of 30 cents per share in the year-ago quarter.

Revenues in the third quarter totaled $133 million, up almost 47.1% year over year. The figure beat the Zacks Consensus Estimate of $132 million. The top line was driven by the strong growth of Livmarli and recently acquired bile acid medicines, Cholbam and Ctexli.

Quarter in Detail

Livmarli’s net product sales were $92 million in the third quarter, reflecting an increase of 56% year over year. Livmarli sales in the United States were $64 million, reflecting strong demand across all indications. In ex-U.S. markets, Livmarli sales were $28 million.

Net product sales of bile acid products, comprising Cholbam and Ctexli tablets, were $40.8 million in the third quarter, reflecting an increase of 31% year over year.

The company did not record any license and other revenues in the reported quarter.

Research and development expenses increased almost 35.6% year over year to $43 million.

Selling, general and administrative expenses totaled $61.9 million, up almost 22.6% from the year-ago quarter’s level.

As of Sept. 30, 2025, Mirum had cash, cash equivalents and investments worth $378 million compared with $321.7 million as of June 30, 2025.

2025 Guidance Tightened

Mirum raised the lower end of its full-year revenue guidance for 2025.

The company now expects revenues to be in the range of $500-$510 million in 2025, compared with the earlier projection of $490-$510 million.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 50.56% due to these changes.

VGM Scores

Currently, Mirum Pharmaceuticals has a strong Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Mirum Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Mirum Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Xenon Pharmaceuticals (XENE Quick QuoteXENE - Free Report) , a stock from the same industry, has gained 14.6%. The company reported its results for the quarter ended September 2025 more than a month ago.

Xenon Pharmaceuticals reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$1.15 for the same period compares with -$0.81 a year ago.

For the current quarter, Xenon Pharmaceuticals is expected to post a loss of $1.20 per share, indicating a change of -42.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.7% over the last 30 days.

Xenon Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.